Electrocore, Inc. cash flow statement
In fiscal 2025, Electrocore, Inc.'s operations generated −$8.2m of cash; it spent $66,000 on capital projects, leaving free cash flow of −$8.3m.
Cash flow statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −25 | −47 | −45 | −20 | −14 | −17 | −15 | −7 | −8 | −10 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Stock-based pay | 0 | 8 | 4 | 3 | 3 | 3 | 2 | 2 | 2 | 3 |
| Capital spending | 0 | 0 | 0 | — | — | — | 0 | — | 0 | 0 |
| Free cash flow | −25 | −47 | −45 | — | — | — | −15 | — | −8 | −10 |
| Free cash flow after stock pay | −26 | −55 | −49 | — | — | — | −17 | — | −10 | −12 |
| Shares issued | — | 78 | — | — | — | — | 8 | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1,363 | −1,255 | −4,355 | −623 | −1,669 | −1,540 | −3,008 | −3,518 |
| Depreciation and amortisation | 185 | 168 | 155 | 121 | 118 | 107 | 21 | 6 |
| Stock-based pay | 400 | 514 | 540 | 505 | 415 | 470 | 1,036 | 755 |
| Capital spending | — | — | 37 | 25 | 4 | 0 | 2 | 4 |
| Free cash flow | — | — | −4,392 | −648 | −1,673 | −1,540 | −3,010 | −3,522 |
| Free cash flow after stock pay | — | — | −4,932 | −1,153 | −2,088 | −2,010 | −4,046 | −4,277 |
| Shares issued | — | — | — | — | — | — | 962 | — |
Compare with peers
- Cytosorbents Corp cash flow
- Utah Medical Products Inc cash flow
- Retractable Technologies Inc cash flow
- Orchestra Biomed Holdings, Inc. cash flow
- Myomo, Inc. cash flow
Head to head: CTSO vs ECORECOR vs UTMDECOR vs RVP
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies